Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E MAP2K1 F53L |
Therapy | Binimetinib + Cetuximab + Encorafenib |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E MAP2K1 F53L | colorectal cancer | predicted - resistant | Binimetinib + Cetuximab + Encorafenib | Case Reports/Case Series | Actionable | In a Phase III (BEACON CRC) trial, two patients with colorectal cancer harboring BRAF V600E progressed on the combination treatment of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), and were found to have acquired MAP2K1 F53L in end-of-treatment ctDNA samples (PMID: 39313594; NCT02928224). | 39313594 |
PubMed Id | Reference Title | Details |
---|---|---|
(39313594) | Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. | Full reference... |